Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 14.3%High 3 · 42.9%

Acute gout attacks · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.3 [0.87, 1.9]
2 studies · 986 participants
High

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 2.2 [1.9, 2.5]
2 studies · 880 participants
Moderate

Pain · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Patient global assessment · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Health related quality of life · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.2 [0.7, 1.93]
3 studies · 1041 participants
High

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.6 [0.49, 5]
3 studies · 1041 participants
High